3 курс / Фармакология / Фармакогенетика_противоопухолевых_препаратов_фундаментальные

Глава 2. Анализ фармакогенетических параметров и инструкций

53.Sugiyama T., Okamoto A., Enomoto T. et al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus

Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial // J. Clin. Oncol. O . J. Am. Soc. Clin. Oncol. 2016. Vol. 34. No. 24. P. 2881–2887.

54.Robert J., Rivory L. Pharmacology of irinotecan // Drugs Today (Barc). Spain. 1998. Vol. 34. No. 9. P. 777–803.

55.Abang A. M. The clinical pharmacology of topoisomerase I inhibitors // Semin. Hematol. 1998. Vol. 35. No. 3 Suppl. 4. P. 13–21.

56.Glimelius B. Benefit-risk assessment of irinotecan in advanced colorectal cancer // Drug Saf. 2005. Vol. 28. No. 5. P. 417–433.

57.Fujita K. et al. Irinotecan, a key chemotherapeutic drug for

metastatic colorectal cancer // World J. Gastroenterol. 2015. Vol. 21. No. 43. P. 12234–12248.

58.Iyer L., King C. D., Whitington P. F. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its

active metabolite (SN-38) in human liver microsomes // J. Clin. Invest. 1998. Vol. 101. No. 4. P. 847–854.

59.De Man F. M., Goey A. K. L., van Schaik R. H. N. et al. Individualization of Irinotecan Treatment: A Review of Pharmacokinet-

ics, Pharmacodynamics, and Pharmacogenetics // Clin. Pharmacokinet. 2018. Vol. 57. No. 10. P. 1229–1254.

60.Wang Y., Shen L., Xu N. et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil // World J. Gastroenterol. 2012. Vol. 18. No. 45. P. 6635–6644.

61.Iyer L., Hall D., Das S. et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism // Clin. Pharmacol. Ther. 1999. Vol. 65. No. 5. P. 576–582.

62.Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? // Genet. Med. 2009. Vol. 11. No. 1. P. 15–20.

63.Swen J. J., Nijenhuis M., de Boer A. et al. Pharmacogenetics: from bench to byte – an update of guidelines // Clin. Pharmacol. Ther. 2011. Vol. 89. No. 5. P. 662–673.

64.Quaranta S., Thomas F. Pharmacogenetics of anti-cancer drugs:

State of the art and implementation – recommendations of the

110

Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/

Список литературы к главе 2

French National Network of Pharmacogenetics // Therapie. 2017. Vol. 72. No. 2. P. 205–215.

65.Etienne-Grimaldi M. C., Boyer J. C., Thomas F. et al. UGT1A1 genotype and irinotecan therapy: general review and implementa-

tion in routine practice // Fundam. Clin. Pharmacol. 2015. Vol. 29. No. 3. P. 219–237.

66.Roco A., Cayún J., Contreras S. et al. Can pharmacogenetics explain e cacy and safety of cisplatin pharmacotherapy? // Front. Genet. 2014. Vol. 5. P. 391.

67.Ghosh S. Cisplatin: The first metal based anticancer drug // Bioorg. Chem. 2019. Vol. 88. P. 102925.

68.Dasari S., Tchounwou P. B. Cisplatin in cancer therapy: molec-

ular mechanisms of action // Eur. J. Pharmacol. 2014. Vol. 740. P. 364–378.

69.Astolfi L., Ghiselli S., Guaran V. et al. Correlation of adverse e ects of cisplatin administration in patients a ected by solid tu-

mours: a retrospective evaluation // Oncol. Rep. 2013. Vol. 29. No. 4. P. 1285–1292.

70.Oun R., Moussa Y. E., Wheate N. J. The side e ects of platinum-

based chemotherapy drugs: a review for chemists // Dalton Trans. 2018. Vol. 47. No. 19. P. 6645–6653.

71.Manohar S., Leung N. Cisplatin nephrotoxicity: a review of the literature // J. Nephrol. 2018. Vol. 31. No. 1. P. 15–25.

72.Langer T., am Zehnho -Dinnesen A., Radtke S. et al. Under-

standing platinum-induced ototoxicity // Trends Pharmacol. Sci. 2013. Vol. 34. No. 8. P. 458–469.

73.Clemens E., de Vries A. C., Pluijm S. F. et al. Determinants of

ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-e ects study // Eur. J. Cancer. 2016. Vol. 69. P. 77–85.

74.Van As J. W., van den Berg H., van Dalen E. C. Platinum-in- duced hearing loss after treatment for childhood cancer // Cochrane database Syst. Rev. 2016. Vol. 2016. No. 8. P. CD010181.

75.Goldsby R. E., Liu Q., Nathan P. C. et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic

leukemia: a report from the Childhood Cancer Survivor Study. // J. Clin. Oncol. O . J. Am. Soc. Clin. Oncol. 2010. Vol. 28. No. 2. P. 324–331.

111

Глава 2. Анализ фармакогенетических параметров и инструкций

76.Schacht J., Talaska A. E., Rybak L. P. Cisplatin and aminogly-

coside antibiotics: hearing loss and its prevention // Anat. Rec. (Hoboken). 2012. Vol. 295. No. 11. P. 1837–1850.

77.Lanvers-Kaminsky C., Ciarimboli G. Pharmacogenetics of drug-

induced ototoxicity caused by aminoglycosides and cisplatin // Pharmacogenomics. 2017. Vol. 18. No. 18. P. 1683–1695.

78.Riedemann L., Lanvers C., Deuster D. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic e ect of cisplatin // Pharmacogenomics J. 2008. Vol. 8. No. 1. P. 23–28.

79.Ciarimboli G., Deuster D., Knief A. et al. Organic cation transporter 2 mediates cisplatin-induced otoand nephrotoxicity and is a

target for protective interventions // Am. J. Pathol. 2010. Vol. 176. No. 3. P. 1169–1180.

80.Xu X., Ren H., Zhou B. et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small

cell lung cancer (NSCLC) patients // Lung Cancer. 2012. Vol. 77. No. 2. P. 438–442.

81.Ross C., Katzov-Eckert H., Dubé M. P. et al. Genetic variants in

TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy // Nat. Genet. 2009. Vol. 41. No. 12.

P.1345–1349.

82.Weinshilboum R. M., Otterness D. M., Szumlanski C. L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase // Annu. Rev. Pharmacol. Toxicol. Annu Rev Pharmacol Toxicol. 1999. Vol. 39. P. 19–52.

83.Yang J. J., Lim J. Y., Huang J. et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer // Clin. Pharmacol. Ther. 2013. Vol. 94. No. 2.

P.252–259.

84.Xu H., Robinson G. W., Huang J. et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss // Nat. Genet. 2015. Vol. 47. No. 3. P. 263–266.

85.Vos H. I., Guchelaar H. J., Gelderblom H. et al. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing

loss in patients with osteosarcoma // Pharmacogenet. Genomics. 2016. Vol. 26. No. 5. P. 243–247.

86.Zámečnı´kova A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer // Expert Opin. Drug Discov. 2014. Vol. 9. No. 1. P. 77–92.

112

Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/

Список литературы к главе 2

87.Drake J. M., Lee J. K., Witte O. N. Clinical targeting of mutated

and wild-type protein tyrosine kinases in cancer // Mol. Cell. Biol. 2014. Vol. 34. № 10. P. 1722–1732.

88.Jiao Q., Bi L., Ren Y. et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance // Mol. Cancer. 2018. Vol. 17. No. 1. P. 36.

89.Zhang J., Yang P. L., Gray N. S. Targeting cancer with small molecule kinase inhibitors. // Nat. Rev. Cancer. 2009. Vol. 9. No. 1.

P.28–39.

90.Chen Y., Zhou D., Tang W. et al. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers //

J.Clin. Pharmacol. 2018. Vol. 58. No. 4. P. 485–493.

91.Li X., Kamenecka T. M., Cameron M. D. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pul-

monary and hepatic toxicities // Chem. Res. Toxicol. 2009. Vol. 22. No. 10. P. 1736–1742.

92.Kumasaka R., Nakamura N., Shirato K. et al. Side e ects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy //

J.Clin. Oncol. 2004. Vol. 22. No. 12. P. 2504–2505.

93.Swaisland H. C., Cantarini M. V., Fuhr R., Holt A. Exploring the

relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics // Clin. Pharmacokinet. Vol. 45. No. 6.

P.633–644.

94.Cohen M. H., Williams G. A., Sridhara R. et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets // Clin. Cancer Res. 2004. Vol. 10. No. 4.

P.1212–1218.

95.Sachse C., Brockmöller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences // Am. J. Hum. Genet. 1997. Vol. 60. No. 2.

P.284–295.

96.Forsythe B., Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer // Drug Saf. 2004. Vol. 27. No. 14. P. 1081–1092.

97.Takimoto T., Kijima T., Otani Y. et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity // Clin. Lung Cancer. 2013. Vol. 14. No. 5. P. 502–507.

113

Глава 2. Анализ фармакогенетических параметров и инструкций

98.Sche er M., Di Gion P., Doroshyenko O. et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazo- lines // Clin. Pharmacokinet. 2011. Vol. 50. No. 6. P. 371–403.

99.Ryan Q. et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2 // Oncologist. 2008. Vol. 13. No. 10.

P.1114–1119.

100.Waknine Y. FDA Approves Lapatinib/Letrozole Combination for Advanced Breast Cancer. 2010. URL: https://www.medscape.com/ viewarticle/716263.

101.Moy B., Goss P. E. Lapatinib: current status and future directions in breast cancer // Oncologist. 2006. Vol. 11. No. 10. P. 1047–1057.

102.Liao J. et al. Lapatinib: new opportunities for management of breast cancer // Breast cancer (Dove Med. Press). 2010. Vol. 2.

P.79–91.

103.MacFarlane R. J., Gelmon K. A. Lapatinib for breast cancer: a

review of the current literature // Expert Opin. Drug Saf. 2011. Vol. 10. No. 1. P. 109–121.

104.Peroukides S., Makatsoris T., Koutras A. et al. Lapatinib-in-

duced hepatitis: a case report // World J. Gastroenterol. 2011. Vol. 17. No. 18. P. 2349–2352.

105.Moy B., Rappold E., Williams L. et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib // J. Clin. Oncol. Wolters Kluwer. 2009. Vol. 27. No. 15_suppl. P. 1043.

106.Spraggs C. F., Budde L. R., Briley L. P. et al. HLA-DQA1*02:01

is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer // J. Clin. Oncol. O . J. Am. Soc. Clin. Oncol. 2011. Vol. 29. No. 6. P. 667–673.

107.Andrade R. J., Lucena M. I., Alonso A. et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease // Hepatology. 2004. Vol. 39. No. 6. P. 1603–1612.

108.Kaplowitz N. Idiosyncratic drug hepatotoxicity // Nat. Rev. Drug Discov. 2005. Vol. 4. No. 6. P. 489–499.

109.Parham L. R., Briley L. P., Li L. et al. Comprehensive genomewide evaluation of lapatinib-induced liver injury yields a single ge-

netic signal centered on known risk allele HLA-DRB1*07:01 // Pharmacogenomics J. 2016. Vol. 16. No. 2. P. 180–185.

110.Phillips E. J., Mallal S. A. Pharmacogenetics of drug hypersensitivity // Pharmacogenomics. 2010. Vol. 11. No. 7. P. 973–987.

114

Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/

Список литературы к главе 2

111.Kumar R., Knick V. B., Rudolph S. K. et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity // Mol. Cancer Ther. 2007. Vol. 6. No. 7.

P.2012–2021.

112.Miyamoto S., Kakutani S., Sato Y. et al. Drug review: Pazopanib // Jpn. J. Clin. Oncol. 2018. Vol. 48. No. 6. P. 503–513.

113.Powles T., Bracarda S., Chen M. et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients // Eur. J. Cancer. 2015. Vol. 51. No. 10.

P.1293–1302.

114.Qosa H., Avaritt B. R., Hartman N. R. et al. In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-

induced hyperbilirubinemia // Cancer Chemother. Pharmacol. 2018. Vol. 82. No. 5. P. 795–802.

115.Johnson T., Xu C., Choueiri T. et al. Genome-wide association study (GWAS) of e cacy and safety endpoints in pazopanibor sunitinib-treated patients with renal cell carcinoma (RCC) // J. Clin. Oncol. Wolters Kluwer. 2014. Vol. 32. No. 15. P. 4503.

116.Motzer R. J., Johnson T., Choueiri T. K. et al. Hyperbilirubinemia

in pazopanibor sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms // Annals of oncology: o cial journal of the European Society for Medical Oncology. 2013. Vol. 24. No. 11. P. 2927–2928.

117.Xu C.-F., Reck B. H., Xue Z. et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism // Br. J. Cancer. 2010. Vol. 102. No. 9. P. 1371–1377.

118.Henriksen J. N., Bøttger P., Hermansen C. K. et al. Pazopanib-

Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: E ect of UGT1A1 Polymorphism on Pazopanib Dose Re-

duction, Safety, and Patient Outcomes // Clin. Genitourin. Cancer. 2020. Vol. 18. No. 1. P. 62–68. P. e2.

119.Xu C.-F. et al. HLA-B*57:01 Confers Susceptibility to Pazopanib-

Associated Liver Injury in Patients with Cancer // Clin. cancer Res. an O . J. Am. Assoc. Cancer Res. 2016. Vol. 22. No. 6.

P.1371–1377.

120.Kantarjian H. M., Giles F., Gattermann N. et al. Nilotinib (for-

merly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is e ective in patients with Philadelphia chromosome-posi-

115

Глава 2. Анализ фармакогенетических параметров и инструкций

tive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance // Blood. 2007. Vol. 110. No. 10.

P.3540–3546.

121.Le Coutre P., Ottmann O. G., Giles F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant acceler-

ated-phase chronic myelogenous leukemia // Blood. 2008. Vol. 111. No. 4. P. 1834–1839.

122.Kantarjian H., Giles F., Wunderle L. et al. Nilotinib in imatinib-

resistant CML and Philadelphia chromosome-positive ALL // N. Engl. J. Med. 2006. Vol. 354. No. 24. P. 2542–2551.

123.Larson R. A., Hochhaus A., Hughes T. P. et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up // Leukemia. 2012. Vol. 26. No. 10. P. 2197–2203.

124.Gresse M., Kim T. D., le Coutre P. Nilotinib // Recent results cancer Res. Fortschritte der Krebsforsch. Prog. dans les Rech. sur le cancer. 2018. Vol. 212. P. 69–85.

125.Singer J. B., Shou Y., Giles F. et al. UGT1A1 promoter poly-

morphism increases risk of nilotinib-induced hyperbilirubinemia // Leukemia. 2007. Vol. 21. No. 11. P. 2311–2315.

126.Giles F. J., Yin O. Q., Sallas W. M. et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia // Eur.

J.Clin. Pharmacol. 2013. Vol. 69. No. 4. P. 813–823.

127.U. S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. URL: https://www.fda.gov/drugs/ science-and-research-drugs/table-pharmacogenomic-biomarkers- drug-labeling (дата обращения: 28.07.2021).

128.European Medicines Agency. URL: https://www.ema.europa.eu/ en (дата обращения: 28.07.2021).

129.Swissmedic. URL: https://www.swissmedic.ch/swissmedic/de/ home.html (дата обращения: 28.07.2021).

130.Health Canada – Canada.ca. URL: https://www.canada.ca/en/ health-canada.html (дата обращения: 28.07.2021).

131.Pharmaceuticals and Medical Devices Agency. URL:

https://www.pmda.go.jp/english/ (дата обращения: 28.07.2021). 132. Otsubo Y., Asahina Y., Noguchi A. et al. Similarities and di er-

ences between US and Japan as to pharmacogenomic biomarker

116

Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/

Список литературы к главе 2

information in drug labels // Drug Metab. Pharmacokinet. 2012. Vol. 27. No. 1. P. 142–149.

133.Shimazawa R., Ikeda M. Di erences in pharmacogenomic biomarker information in package inserts from the United States,

the United Kingdom and Japan // J. Clin. Pharm. Ther. 2013. Vol. 38. No. 6. P. 468–475.

134.Ehmann F., Caneva L., Prasad K. et al. Pharmacogenomic infor-

mation in drug labels: European Medicines Agency perspective // Pharmacogenomics J. 2015. Vol. 15. No. 3. P. 201–210.

135.Jeiziner C., Suter K., Wernli U. et al. Pharmacogenetic information in Swiss drug labels – a systematic analysis // Pharmacogenomics J. 2021. Vol. 21. No. 4. P. 423–434.

136.Государственный реестр лекарственных средств. URL:

http://grls.rosminzdrav.ru/Default.aspx (дата обращения: 28.07.2021).

137.Yim W. W., Yetisgen M., Harris W. P., Kwan S. W. Natural Lan-

guage Processing in Oncology: A Review // JAMA Oncol. 2016. Vol. 2. No. 6. P. 797–804.

138.U. S. Food and Drug Administration. Prescribing information for “XELODA”. URL: https://www.accessdata.fda.gov/scripts/cder/ daf/index.cfm?event=overview.process&ApplNo=020896 (дата обращения: 28.07.2021).

139.European Medicines Agency. Prescribing information for “Xeloda”. URL: https://www.ema.europa.eu/en/medicines/human/EPAR/ xeloda (дата обращения: 28.07.2021).

140.Государственный реестр лекарственных средств. Регистрационное удостоверение капецитабина «Капецитовер ». URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 3582ee35-df68-4fbd-8363-15471d600dd5&t= (дата обращения: 28.07.2021).

141.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Капецитабин Д-р Редди’с». URL: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=577201c0-cef1-4103-834c- 2eab4f66cc29&t= (дата обращения: 28.07.2021).

142.Государственный реестр лекарственных средств. Регистрационное удостоверение лекарственного препарата капецитабина «Ка- пецитабин-ТЛ». URL: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=5e862786-4c46-402c-a5c8- 17d52645e736&t= (дата обращения: 28.07.2021).

117

Глава 2. Анализ фармакогенетических параметров и инструкций

143.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Тутабин ». URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=bcb2bdb1-57fe-4f84-a479-fad59b726e7e&t= (дата обращения: 28.07.2021).

144.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Кселода ». URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=09943125-d3fe-4303-b77f-7f2d1d26e2a4&t= (дата обращения: 28.07.2021).

145.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Капецитабин» (ООО «Нанофарма Девелопмент»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= e6dd6a54-7dac-4fe5-9f68-dcb413fc9945&t= (дата обращения: 28.07.2021).

146.Государственный реестр лекарственных средств. Регистрационное удостоверение лекарственного препарата капецитабина «Капецитабин» (ООО «Озон Медика»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= fddd08d7-7f55-49bb-9ac7-a6454124b27d&t= (дата обращения: 28.07.2021).

147.Государственный реестр лекарственных средств. Регистрационное удостоверение лекарственного препарата капецитабина «Капецитабин» (ООО «Джодас Экспоим»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 23be3b8b-d005-4b8f-b503-63cad2059882&t= (дата обращения: 28.07.2021).

148.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Ксалвобин». URL: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=757fda52-78b2-4f23-8dc0- f080d c7caa&t= (дата обращения: 28.07.2021).

149.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина «Капаметин ФС». URL: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=6c2cf23a-2100-4a30-9716- 5daf3d7fb818&t= (дата обращения: 28.07.2021).

150.Государственный реестр лекарственных средств. Регистрационное удостоверение лекарственного препарата капецитабина

118

Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/

Список литературы к главе 2

«Капецитабин» (АО «Фармасинтез-Норд»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 76 2bf5-4ec6-4637-ac57-454ab2dc3bc3&t= (дата обращения: 28.07.2021).

151.Государственный реестр лекарственных средств. Регистрационное удостоверение лекарственного препарата капецитабина «Капецитабин» (ЗАО «БИОКАД»). URL: http://grls.rosminzdrav.ru/

Grls_View_v2.aspx?routingGuid=a4aa20f6-18bf-48dd-af44- ac0083b bef&t= (дата обращения: 28.07.2021).

152.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата капецитабина

«Кабецин». URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx? routingGuid=14d 6e7-52e1-495b-979b-7677202a85e8&t= (дата обращения: 28.07.2021).

153. U. S. Food and Drug	Administration. Prescribing information
for “FLUOROURACIL”.	URL: https://www.accessdata.fda.gov/

scripts/cder/daf/index.cfm?event= overview.process&ApplNo=012209 (дата обращения: 28.07.2021).

154. U. S. Food and Drug Administration. Prescribing information for “CARAC”. URL: https://www.accessdata.fda.gov/scripts/cder/ daf/index.cfm?event=overview.process&ApplNo=020985 (дата обращения: 28.07.2021).

155.Cohen P. R. Topical application of 5-fluorouracil 5 percent cream

associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil // Dermatol. Online J. 2018. Vol. 24. No. 4.

156.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата фторурацила «ФТОРУРАЦИЛ» (ООО «ИРВИН 2»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 082974ce-aac5-4ac5-9183-b476f8475145&t= (дата обращения: 28.07.2021).

157.Государственный реестр лекарственных средств. Регистраци-

онное удостоверение лекарственного препарата фторурацила «Фторурацил» (АО «Фармасинтез-Норд»). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 09899355-e368-48e8-af15-c20a1bfa2674&t= (дата обращения: 28.07.2021).

119